Primary and secondary end points were demonstrated in a phase 3 trial of subcutaneous marstacimab as treatment for patients ...

New data show sharp growth in pharmacists’ clinical roles, from the intensive care unit to outpatient chronic disease ...

Iptacopan targets one of the major proteins involved in the enzymes of the alternative pathway of complement, explains Carla ...

The hazard of the progression of intermediate age-related macular degeneration (iAMD) was higher in those whose complement ...

John Mascarenhas, MD, discusses the rationale, mechanism, and design of the phase 1 INCA33989-101 and -102 trials investigating a CAL-R–targeted antibody for patients with essential thrombocythemia.

Panelists discuss recent phase 3 trial results of a novel oral agent for idiopathic pulmonary fibrosis (IPF) and progressive ...

On-body delivery systems for subcutaneous isatuximab could enable patient self-administration, according to Xavier Leleu, MD, PhD, improving convenience and transforming treatment for ...

Controversy surrounds the Advisory Committee on Immunization Practices’ (ACIP) first meeting under new leadership as vaccine skeptics join the panel.

Compared with tezepelumab, solrikitug demonstrated unique epitope binding and superior potency across several assays.

The phase 3 IRAKLIA trial found that subcutaneous isatuximab delivered via an on-body system was as effective and safe as intravenous (IV) administration in relapsed/refractory multiple myeloma, ...

Patients with relapsed/refractory myeloma from lower socioeconomic groups face worse quality of life, even in countries with universal health care, according to Francesco Sparano, MSc, of the ...

Long-term CARTITUDE-1 data show ciltacabtagene autoleucel (cilta-cel) may offer lasting remission and survival in relapsed/refractory multiple myeloma, according to Sundar Jagannath, MBBS, of the ...